- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted therapy for osteosarcoma: a review
Authors
Keywords
-
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-02-20
DOI
10.1007/s00432-023-04614-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pazopanib in Patients with Osteosarcoma Metastatic to the Lung: Phase 2 Study Results and the Lessons for Tumor Measurement
- (2022) Paul Frankel et al. Journal of Oncology
- Osteosarcoma: A Surveillance, Epidemiology, and End Results program‐based analysis from 1975 to 2017
- (2022) Sarah Cole et al. CANCER
- Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
- (2021) Sarah K. Madden et al. Molecular Cancer
- Predictive model for the 5-year survival status of osteosarcoma patients based on the SEER database and XGBoost algorithm
- (2021) Jiuzhou Jiang et al. Scientific Reports
- MDM2 Amplified Sarcomas: A Literature Review
- (2021) Raf Sciot Diagnostics
- Safety, anti-tumor activity, and biomarker analysis in a phase 1 trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
- (2021) Naoko Takebe et al. CLINICAL CANCER RESEARCH
- Angiopoietin inhibitors: A review on targeting tumor angiogenesis
- (2021) Digna Parmar et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Current status and novel strategy of CML
- (2021) Kiyomi Morita et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development–Review
- (2021) Paweł Łukasik et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Advances in targeted therapy for osteosarcoma based on molecular classification
- (2021) Yingqian Chen et al. PHARMACOLOGICAL RESEARCH
- Update on Osteosarcoma
- (2021) Rebekah Belayneh et al. Current Oncology Reports
- Rhaponticin suppresses osteosarcoma through the inhibition of PI3K-Akt-mTOR pathway
- (2021) Suresh Mickymaray et al. SAUDI JOURNAL OF BIOLOGICAL SCIENCES
- The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis
- (2021) George N. Tzanakakis et al. Cancers
- Targeting the VEGF Pathway in Osteosarcoma
- (2021) Tarek Assi et al. Cells
- Assessment of Efficiency and Safety of Apatinib in Advanced Bone and Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis
- (2021) Zuoyao Long et al. Frontiers in Oncology
- Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease
- (2021) HIROMICHI OSHIRO et al. ANTICANCER RESEARCH
- Current research progress in targeted anti‐angiogenesis therapy for osteosarcoma
- (2021) Yun Liu et al. CELL PROLIFERATION
- IGF-1 and IGFBP-3 in Inflammatory Cachexia
- (2021) Ana Isabel Martín et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer
- (2021) Peter Q. Huang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches
- (2021) Punit Saraon et al. ONCOGENE
- New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
- (2021) Yu He et al. PHARMACOLOGICAL RESEARCH
- Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
- (2021) Lu Xie et al. Oncology Letters
- Research models and mesenchymal/epithelial plasticity of osteosarcoma
- (2021) Xiaobin Yu et al. Cell and Bioscience
- TP53 in Biology and Treatment of Osteosarcoma
- (2021) Kamil Jozef Synoradzki et al. Cancers
- Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6–Cyclin D–Rb pathway
- (2021) Deli Wang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Treatment for liver cancer: From sorafenib to natural products
- (2021) Shuli Man et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring
- (2021) Jenny F. Seligmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Osteosarcoma: An Evolving Understanding of a Complex Disease
- (2021) John H. Alexander et al. JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS
- Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial
- (2021) Yoshiaki Nakamura et al. NATURE MEDICINE
- Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations
- (2021) Xiangbing Meng et al. Frontiers in Medicine
- Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors
- (2020) Dima A. Sabbah et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
- (2020) Matthew H. Taylor et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial
- (2020) Antoine Italiano et al. LANCET ONCOLOGY
- Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond
- (2020) Caterina Marchiò et al. SEMINARS IN CANCER BIOLOGY
- The role of autophagy in resistance to targeted therapies
- (2020) Luigi Mele et al. CANCER TREATMENT REVIEWS
- Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma
- (2020) Ran Wei et al. JOURNAL OF ORTHOPAEDIC RESEARCH
- Piceatannol Suppresses the Proliferation and Induced Apoptosis of Osteosarcoma Cells Through PI3K/AKT/mTOR Pathway
- (2020) Bin Wang et al. Cancer Management and Research
- Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
- (2020) Charles Pottier et al. Cancers
- Pharmacogenetics for severe adverse drug reactions induced by molecular‐targeted therapy
- (2020) Chihiro Udagawa et al. CANCER SCIENCE
- Down‐regulation of PDGFRβ suppresses invasion and migration in osteosarcoma cells by influencing epithelial–mesenchymal transition
- (2020) Sining Xing et al. FEBS Open Bio
- Aurora-B Promotes Osteosarcoma Cell Growth and Metastasis Through Activation of the NPM1/ERK/NF-κβ/MMPs Axis
- (2020) Honghai Song et al. Cancer Management and Research
- Molecular Biology of Osteosarcoma
- (2020) Anna M. Czarnecka et al. Cancers
- Clinical efficiency of epigenetic drugs therapy in bone malignancies
- (2020) Filomena de Nigris et al. BONE
- The next tier of EGFR resistance mutations in lung cancer
- (2020) Hannah L. Tumbrink et al. ONCOGENE
- Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
- (2020) Vincent Chau et al. Cancer Management and Research
- Aurora-B knockdown inhibits osteosarcoma metastasis by inducing autophagy via the mTOR/ULK1 pathway
- (2020) Xin Wu et al. Cancer Cell International
- Overactivation of the IGF signalling pathway in osteosarcoma: a potential therapeutic target?
- (2020) Baptiste Ameline et al. Journal of Pathology Clinical Research
- Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma
- (2019) Fan Tang et al. JOURNAL OF ORTHOPAEDIC RESEARCH
- A Phase 2 Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase 1 and Pilot Consortium ADVL0921)
- (2019) Yael P. Mosse et al. CLINICAL CANCER RESEARCH
- Clinical genomic sequencing of pediatric and adult osteosarcoma reveals distinct molecular subsets with potentially targetable alterations
- (2019) Yoshiyuki Suehara et al. CLINICAL CANCER RESEARCH
- Cancer drug resistance: A fleet to conquer
- (2019) Showket Hussain et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
- (2019) Lara E. Davis et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting mTOR for cancer therapy
- (2019) Hui Hua et al. Journal of Hematology & Oncology
- Genome-wide CRISPR-Cas9 screen reveals selective vulnerability of ATRX-mutant cancers to WEE1 inhibition
- (2019) Junbo Liang et al. CANCER RESEARCH
- CSN5 controls the growth of osteosarcoma via modulating the EGFR/PI3K/Akt axis
- (2019) Zongmiao Wan et al. EXPERIMENTAL CELL RESEARCH
- The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model
- (2019) Takashi Higuchi et al. Translational Oncology
- ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures
- (2019) Zulekha A. Qadeer et al. CANCER CELL
- Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics
- (2019) Anabel Sorolla et al. ONCOGENE
- Caveolin-1 Expression Together with VEGF can be a Predictor for Lung Metastasis and Poor Prognosis in Osteosarcoma
- (2019) Fatma El-Zahraa Ammar Mohamed et al. PATHOLOGY & ONCOLOGY RESEARCH
- WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells
- (2019) Tatiana N. Moiseeva et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors. A COG Phase I Consortium Report (ADVL1312)
- (2019) Kristina A. Cole et al. CLINICAL CANCER RESEARCH
- Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma
- (2018) Yubing Zhou et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Does ATRX germline variation predispose to osteosarcoma? Three additional cases of osteosarcoma in two ATR-X syndrome patients
- (2018) Julien Masliah-Planchon et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
- (2018) Hye Jeong Park et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells
- (2018) Loredana Zocchi et al. Oncotarget
- Genome-Informed Targeted Therapy for Osteosarcoma
- (2018) Leanne C Sayles et al. Cancer Discovery
- Identification of a novel gene fusion in ALT positive osteosarcoma
- (2018) Emily Mason-Osann et al. Oncotarget
- Response to Pazopanib in Patients With Relapsed Osteosarcoma
- (2018) Kunal R. Elete et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Florence Duffaud et al. LANCET ONCOLOGY
- A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy
- (2017) Fariba Navid et al. INTERNATIONAL JOURNAL OF CANCER
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
- (2017) Alison M. Schram et al. Nature Reviews Clinical Oncology
- Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma
- (2017) Kuisheng Liu et al. Cell Death & Disease
- SPC24 promotes osteosarcoma progression by increasing EGFR/MAPK signaling
- (2017) Jun Sheng et al. Oncotarget
- mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review)
- (2016) Kai Hu et al. ONCOLOGY REPORTS
- Targeting WEE1 Kinase in Cancer
- (2016) Christopher J. Matheson et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer
- (2016) Yubing Zhou et al. Oncotarget
- Generation of Osteosarcomas from a Combination of Rb Silencing and c-Myc Overexpression in Human Mesenchymal Stem Cells
- (2016) Jir-You Wang et al. Stem Cells Translational Medicine
- Impact of MYC in regulation of tumor cell metabolism
- (2015) Therese Wahlström et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells
- (2015) Sayaka I. Yamaguchi et al. CANCER SCIENCE
- Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T cells against zoledronate-sensitized osteosarcoma cells
- (2015) Meng Liu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance
- (2015) Florian Sevelda et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
- (2015) Giovanni Grignani et al. LANCET ONCOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency
- (2015) Michal Kovac et al. Nature Communications
- Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression
- (2015) Liu Yang et al. Oncotarget
- SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression
- (2014) S. Wang et al. CANCER RESEARCH
- Targeting the BRCA1/2 Tumor Suppressors
- (2014) Eliot Rosen et al. CURRENT DRUG TARGETS
- Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models
- (2014) Emmy D.G. Fleuren et al. INTERNATIONAL JOURNAL OF CANCER
- Aurora-A kinase: Potential tumor marker of osteosarcoma
- (2014) Xiaozhong Zhu et al. Journal of Cancer Research and Therapeutics
- Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group
- (2014) Lars M. Wagner et al. PEDIATRIC BLOOD & CANCER
- Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
- (2014) Xiang Chen et al. Cell Reports
- Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
- (2013) E Tavanti et al. BRITISH JOURNAL OF CANCER
- VEGFR, RET, and RAF/MEK/ERK Pathway Take Part in the Inhibition of Osteosarcoma MG63 Cells with Sorafenib Treatment
- (2013) Jiong Mei et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
- (2013) J. Rader et al. CLINICAL CANCER RESEARCH
- The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
- (2013) Y. Pignochino et al. CLINICAL CANCER RESEARCH
- Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group
- (2013) Brenda Weigel et al. PEDIATRIC BLOOD & CANCER
- Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas
- (2013) Jenny M. Kreahling et al. PLoS One
- Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group
- (2012) David Ebb et al. JOURNAL OF CLINICAL ONCOLOGY
- c-Myc Overexpression Promotes Osteosarcoma Cell Invasion Via Activation of MEK-ERK Pathway
- (2012) Gang Han et al. ONCOLOGY RESEARCH
- A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
- (2011) G. Grignani et al. ANNALS OF ONCOLOGY
- WEE1 inhibition sensitizes osteosarcoma to radiotherapy
- (2011) Jantine PosthumaDeBoer et al. BMC CANCER
- Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma
- (2011) J. H. W. Pahl et al. CLINICAL CANCER RESEARCH
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
- (2011) Sant P. Chawla et al. JOURNAL OF CLINICAL ONCOLOGY
- Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma
- (2011) William W. Lockwood et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces the Apoptosis of Osteosarcoma Cells
- (2011) W. Fu et al. MOLECULAR CANCER THERAPEUTICS
- Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines
- (2009) Z. Duan et al. MOLECULAR CANCER THERAPEUTICS
- Role of platelet-derived growth factors in physiology and medicine
- (2008) J. Andrae et al. GENES & DEVELOPMENT
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started